{"id":70076,"date":"2026-07-16T15:58:55","date_gmt":"2026-07-16T07:58:55","guid":{"rendered":"https:\/\/flcube.com\/?p=70076"},"modified":"2026-07-16T15:58:56","modified_gmt":"2026-07-16T07:58:56","slug":"merck-kgaas-enpatoran-receives-fda-breakthrough-therapy-designation-for-cutaneous-lupus","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70076","title":{"rendered":"Merck KGaA&#8217;s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Merck KGaA<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:ETR\">ETR: MRK<\/a>) announced on July 8, 2026, that the <strong>US Food and Drug Administration (FDA)<\/strong> has granted <strong>Breakthrough Therapy designation<\/strong> to its investigational drug <strong>enpatoran<\/strong> for the treatment of <strong>lupus with active cutaneous manifestations<\/strong>. Enpatoran represents a potential first-in-class targeted therapy specifically designed for lupus patients presenting with skin involvement.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-key-details\" class=\"wp-block-heading\">Regulatory Milestone | Key Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Merck KGaA (ETR: MRK), Darmstadt, Germany<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>Enpatoran<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>FDA Breakthrough Therapy Designation<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Lupus with active cutaneous manifestations<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>July 8, 2026<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Investigational<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 id=\"h-molecular-characteristics\" class=\"wp-block-heading\">Molecular Characteristics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class:<\/strong> Oral, selective toll-like receptor (TLR) 7\/8 inhibitor<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Oral dosing<\/li>\n\n\n\n<li><strong>Target Specificity:<\/strong> Dual inhibition of TLR7 and TLR8 pathways<\/li>\n\n\n\n<li><strong>Therapeutic Innovation:<\/strong> First targeted therapy specifically for cutaneous lupus manifestations<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-biological-rationale\" class=\"wp-block-heading\">Biological Rationale<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Enpatoran is designed to <strong>modulate pathways central to lupus-related inflammation<\/strong> by selectively inhibiting TLR7 and TLR8, which play critical roles in the activation of innate immune responses and production of type I interferons\u2014key drivers of lupus pathogenesis, particularly in cutaneous manifestations.<\/p>\n\n\n\n<h2 id=\"h-clinical-significance-amp-market-opportunity\" class=\"wp-block-heading\">Clinical Significance &amp; Market Opportunity<\/h2>\n\n\n\n<h3 id=\"h-unmet-medical-need\" class=\"wp-block-heading\">Unmet Medical Need<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cutaneous lupus<\/strong> affects approximately <strong>70-85%<\/strong> of systemic lupus erythematosus (SLE) patients<\/li>\n\n\n\n<li>Current treatments rely on <strong>non-specific immunosuppressants<\/strong>, antimalarials, and corticosteroids<\/li>\n\n\n\n<li><strong>No approved targeted therapies<\/strong> exist specifically for cutaneous lupus manifestations<\/li>\n\n\n\n<li>Significant impact on <strong>quality of life<\/strong> due to visible skin lesions, photosensitivity, and scarring<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-competitive-landscape\" class=\"wp-block-heading\">Competitive Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Enpatoran could become the <strong>first targeted therapy<\/strong> approved specifically for cutaneous lupus<\/li>\n\n\n\n<li>Differentiates from existing SLE therapies that primarily address systemic symptoms<\/li>\n\n\n\n<li>Addresses a <strong>$1.2 billion addressable market<\/strong> in the US alone for cutaneous lupus treatments<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications-for-merck-kgaa\" class=\"wp-block-heading\">Strategic Implications for Merck KGaA<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The Breakthrough Therapy designation provides Merck KGaA with:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Intensive FDA guidance<\/strong> on efficient clinical development<\/li>\n\n\n\n<li><strong>Priority review<\/strong> upon marketing application submission<\/li>\n\n\n\n<li><strong>Rolling review<\/strong> capability for faster approval timelines<\/li>\n\n\n\n<li>Enhanced <strong>investor and market confidence<\/strong> in the asset&#8217;s potential<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This designation validates Merck KGaA&#8217;s strategic focus on <strong>immune-mediated inflammatory diseases<\/strong> and strengthens its position in the competitive lupus therapeutics market, which has seen limited innovation despite significant unmet needs.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The company&#8217;s pipeline now includes multiple assets targeting different aspects of lupus pathophysiology, positioning it as a serious contender in this high-value therapeutic area.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory designations, clinical development, and market opportunities. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck KGaA (ETR: MRK) announced on July 8, 2026, that the US Food and Drug&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[65,1147,120],"class_list":["post-70076","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-etr-mrk","tag-merck"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Merck KGaA&#039;s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck KGaA (ETR: MRK) announced on July 8, 2026, that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to its investigational drug enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran represents a potential first-in-class targeted therapy specifically designed for lupus patients presenting with skin involvement.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70076\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck KGaA&#039;s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus\" \/>\n<meta property=\"og:description\" content=\"Merck KGaA (ETR: MRK) announced on July 8, 2026, that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to its investigational drug enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran represents a potential first-in-class targeted therapy specifically designed for lupus patients presenting with skin involvement.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70076\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-16T07:58:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-16T07:58:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70076#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70076\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Merck KGaA&#8217;s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus\",\"datePublished\":\"2026-07-16T07:58:55+00:00\",\"dateModified\":\"2026-07-16T07:58:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70076\"},\"wordCount\":400,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"ETR: MRK\",\"Merck\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70076#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70076\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70076\",\"name\":\"Merck KGaA's Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-16T07:58:55+00:00\",\"dateModified\":\"2026-07-16T07:58:56+00:00\",\"description\":\"Merck KGaA (ETR: MRK) announced on July 8, 2026, that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to its investigational drug enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran represents a potential first-in-class targeted therapy specifically designed for lupus patients presenting with skin involvement.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70076#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70076\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70076#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck KGaA&#8217;s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Merck KGaA's Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus - Insight, China&#039;s Pharmaceutical Industry","description":"Merck KGaA (ETR: MRK) announced on July 8, 2026, that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to its investigational drug enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran represents a potential first-in-class targeted therapy specifically designed for lupus patients presenting with skin involvement.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70076","og_locale":"en_US","og_type":"article","og_title":"Merck KGaA's Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus","og_description":"Merck KGaA (ETR: MRK) announced on July 8, 2026, that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to its investigational drug enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran represents a potential first-in-class targeted therapy specifically designed for lupus patients presenting with skin involvement.","og_url":"https:\/\/flcube.com\/?p=70076","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-16T07:58:55+00:00","article_modified_time":"2026-07-16T07:58:56+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70076#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70076"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Merck KGaA&#8217;s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus","datePublished":"2026-07-16T07:58:55+00:00","dateModified":"2026-07-16T07:58:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70076"},"wordCount":400,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","ETR: MRK","Merck"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70076#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70076","url":"https:\/\/flcube.com\/?p=70076","name":"Merck KGaA's Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-16T07:58:55+00:00","dateModified":"2026-07-16T07:58:56+00:00","description":"Merck KGaA (ETR: MRK) announced on July 8, 2026, that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to its investigational drug enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran represents a potential first-in-class targeted therapy specifically designed for lupus patients presenting with skin involvement.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70076#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70076"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70076#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Merck KGaA&#8217;s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70076","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70076"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70076\/revisions"}],"predecessor-version":[{"id":70078,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70076\/revisions\/70078"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70076"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70076"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70076"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}